Ottimo Pharma Welcomes New Leadership
Ottimo Pharma, a dynamic biotechnology firm, is thrilled to announce the onboarding of highly esteemed professionals to its leadership team. This move signals an exciting phase for the company, known for its innovative approaches in developing groundbreaking cancer therapies.
Meet the New Leadership Team
David Epstein Takes the Helm
David Epstein joins Ottimo Pharma as Chair and Chief Executive Officer. With an impressive track record, he previously served as the CEO of Seagen and has over 30 years in drug development and commercialization. David’s leadership is expected to steer Ottimo Pharma towards achieving its ambitious goals.
Expertise from the Medical Frontline
Joining David is Mehdi Shahidi as Head of Development and Chief Medical Officer. Mehdi brings extensive experience in oncology, having spent two decades overseeing the clinical development of various drugs during his tenure at Boehringer Ingelheim. His background positions him well to harness Ottimo's innovative approach to cancer treatment.
James Sabry Enhances Strategic Direction
Another notable addition is James Sabry, who comes on board as Vice-Chair of the Board of Directors. His previous role as Head of Pharma Partnering at Roche gives him a unique perspective on business development, making him a key player in Ottimo’s strategic initiatives.
Jankistomig: A Novel Cancer Therapy
Ottimo Pharma is making strides with its lead candidate, Jankistomig, a bi-functional antibody designed to target PD1 and VEGFR2 pathways. This innovative therapy aims to tackle cancer through immune checkpoint inhibition and angiogenesis in a single platform.
David Epstein remarked, "This new medicine is exquisitely designed and offers large potential benefits to patients across various solid tumors. We are excited to expand the team and fulfill our commitments to patients."
Jankistomig aims to improve treatment outcomes while minimizing the adverse effects commonly associated with cancer therapies. By effectively blocking the PD1 and VEGF pathways, it enhances tumor immune cell distribution without the negative impacts often linked to vascular endothelial growth factor.
Commitment to Transforming Cancer Treatment
Ottimo Pharma is dedicated to changing the landscape of cancer treatment. With a firm belief in the therapy's potential, the company has devoted the past few years to rigorously pre-clinical testing, setting the stage for an Investigational New Drug application (IND) that they plan to submit by late 2025.
Francesco De Rubertis, a Board Member at Ottimo Pharma and Partner at Medicxi, expressed confidence in the leadership team's collective expertise, anticipating significant advancements in cancer therapy from the foundational insight supplied by Jonny Finlay, the class's scientific founder.
Why Ottimo Pharma Matters in the Biotech Space
Founded in 2020, Ottimo Pharma stands at the forefront of advancing cancer therapies, co-founded with Medicxi. Its commitment to innovation in treating solid tumors places it in a prominent position within the biotech industry. With industry veterans like David Epstein, Mehdi Shahidi, and James Sabry steering the course, the company's ambitions to revolutionize cancer care are well-grounded.
This new phase for Ottimo Pharma illustrates its determination to address unmet medical needs through pioneering therapeutics. With plans for upcoming regulatory filings and further research, they are poised to impact patient outcomes significantly. As Ottimo Pharma emerges from its stealth mode, continued progress and breakthroughs should be expected in the coming years.
Frequently Asked Questions
What is Ottimo Pharma's primary focus?
Ottimo Pharma is devoted to developing innovative cancer therapies, particularly the Jankistomig antibody targeting PD1 and VEGFR2.
Who are the key members of Ottimo Pharma's leadership team?
David Epstein is the CEO, Mehdi Shahidi is the Chief Medical Officer, and James Sabry is the Vice-Chair of the Board.
What is Jankistomig?
Jankistomig is a PD1-VEGFR2 bi-functional antibody intended for targeting immune checkpoint pathways in cancer treatment.
When does Ottimo Pharma plan to file for an IND?
Ottimo Pharma anticipates submitting its IND application by late 2025.
What is the significance of Jankistomig's dual-pathway approach?
This dual-pathway approach aims to enhance treatment efficacy while reducing adverse effects commonly associated with traditional cancer therapies.
